We are live on ! Find out more
EGRX

Eagle Pharmaceuticals, Inc.
EGRX

Delisted

EGRX was delisted on the 2nd of October, 2024.

Back to rankings

9 hedge funds and large institutions have $38.8K invested in Eagle Pharmaceuticals, Inc. in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 55 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

86% less funds holding

Funds holding: 65 → 9 (-56)

100% less capital invested

Capital invested by funds: $31.9M → $38.8K (-$31.9M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 55

Holders
9
Holders Change
-56
Holders Change %
-86.15%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
3
Closed
55
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Simplex Trading
Simplex Trading
Illinois
+$27.9K
2
XT
XTX Topco
Cayman Islands
+$3.3K

Top Sellers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
-$8.79M
2
ACM
AIGH Capital Management
Maryland
-$4.52M
3
Citigroup
Citigroup
New York
-$3.73M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$2.16M
5
AQR Capital Management
AQR Capital Management
Connecticut
-$1.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
– -$395K -105,846 Closed
Invesco
27
Invesco
Georgia
– -$309K -82,775 Closed
DCM
28
DGS Capital Management
New Jersey
– -$268K -71,728 Closed
USPCM
29
Union Square Park Capital Management
New York
– -$212K -56,963 Closed
D.E. Shaw & Co
30
D.E. Shaw & Co
New York
– -$204K -54,625 Closed
Bank of America
31
Bank of America
North Carolina
– -$190K -51,006 Closed
Deutsche Bank
32
Deutsche Bank
Germany
– -$182K -48,800 Closed
TI
33
Trexquant Investment
Connecticut
– -$163K -43,723 Closed
Royal Bank of Canada
34
Royal Bank of Canada
Ontario, Canada
– -$138K -36,925 Closed
State Street
35
State Street
Massachusetts
– -$134K -35,820 Closed
Northern Trust
36
Northern Trust
Illinois
– -$119K -31,955 Closed
BCM
37
Bridgeway Capital Management
Texas
– -$119K -31,900 Closed
Goldman Sachs
38
Goldman Sachs
New York
– -$117K -31,495 Closed
PP
39
PDT Partners
New York
– -$112K -30,011 Closed
Fidelity Investments
40
Fidelity Investments
Massachusetts
– -$106K -28,348 Closed
Citadel Advisors
41
Citadel Advisors
Florida
– -$97K -26,013 Closed
Jane Street
42
Jane Street
New York
– -$96.4K -25,837 Closed
BNP Paribas Financial Markets
43
BNP Paribas Financial Markets
France
– -$67K -17,976 Closed
Creative Planning
44
Creative Planning
Kansas
– -$58.5K -15,686 Closed
VPIM
45
Vanguard Personalized Indexing Management
California
– -$57.9K -15,530 Closed
RA
46
Royce & Associates
New York
– -$51.6K -13,821 Closed
T. Rowe Price Associates
47
T. Rowe Price Associates
Maryland
– -$50K -13,300 Closed
William Blair & Company
48
William Blair & Company
Illinois
– -$48.3K -12,952 Closed
VF
49
Virtu Financial
New York
– -$48K -12,890 Closed
HSBC Holdings
50
HSBC Holdings
United Kingdom
– -$45K -11,396 Closed
1
2
3

EGRX Hedge Fund Activity: Q4 2024 in Review

9 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q4 2024, worth a combined $38.8K — down 100% from $31.9M a quarter earlier.

Sellers outnumbered buyers: 55 funds closed out of EGRX and 0 opened new positions — a net loss of 55 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was Simplex Trading, adding an estimated $27.9K. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $8.79M sold.

  • 9 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q4 2024, down from 65 in Q3 2024.
  • Funds reported $38.8K of Eagle Pharmaceuticals, Inc. stock for Q4 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Eagle Pharmaceuticals, Inc. positions in Q4 2024 and 55 closed out, a net change of -55 holders.
  • The largest Eagle Pharmaceuticals, Inc. buyer in Q4 2024 was Simplex Trading, an estimated $27.9K added.
  • The largest Eagle Pharmaceuticals, Inc. seller in Q4 2024 was Nantahala Capital Management, an estimated $8.79M sold.

Based on aggregated 13F filings for Q4 2024.